Search Within

Parisa Momtaz

Formats
  1. Journal Article (27)
  2. Meeting Abstract (22)
  3. Book Section (4)
  4. Research Letter (1)
Groups
  1. Department of Medicine (54)
  2. Melanoma Disease Management Team (54)
  3. Melanoma and Immunotherapeutics Service (54)
  4. Solid Tumor Oncology Division (54)
  5. Survivorship Research (54)
  6. Weinberg Fellows (54)

More Groups

People
  1. Michael Postow (36)
  2. Alexander Shoushtari (32)
  3. Paul Chapman (31)
  4. Jedd Wolchok (29)
  5. Margaret Callahan (29)
  6. Katherine Panageas (25)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (5)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Pocket Oncology (4)
  3. Clinical Cancer Research (3)
  4. Nature (3)
  5. JAMA Oncology (2)
  6. Oncotarget (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Oxford University Press (4)
  3. Wolters Kluwer Health | Lippincott Williams & Wilkins (4)
  4. American Association for Cancer Research (3)
  5. Nature Publishing Group (3)
  6. Wiley Blackwell (3)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Shoushtari, A. N.; Armenia, J.; Arora, A.; Rojas-Zamalloa, J.; Warner, A. B.; Derr, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Coit, D. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma
    Meeting Abstract

    Gottesdiener, L. S.; Gormally, M.; Armenia, J.; El-Jalby, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Wolchok, J. D.; Chapman, P. B.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Journal Article

    Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab
    Journal Article

    Friedman, C. F.; Clark, V.; Raikhel, A. V.; Barz, T.; Shoushtari, A. N.; Momtaz, P.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; Hellmann, M. D.; more...
    JNCI: Journal of the National Cancer Institute (2017)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone
    Meeting Abstract

    Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save